Please assess the completion status of the following clinical trial:

Trial Title: Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* On peritoneal dialysis at least 3 months with a Kt/V of ≥ 1.7~* Use of Automated Peritoneal Dialysis~* Serum phosphate \> 5.5 mg/dL or \<5.5 mg/dL on a binder other than velphoro~* Serum albumin ≤ 3.7 g/dL~* Able to provide consent~* Ability to complete self-reported questionnaire~Exclusion Criteria:~* Inadequate dialysis~* Current use of sucroferric oxyhydroxide~* Significant comorbid conditions that lead the investigator to conclude that life expectancy is less than 6 months~* Active malignancy~* Recent episode of peritonitis~* Pregnancy or planning to become pregnant~* Anticipated kidney transplantation within 6 months~* Factors judged to limit adherence to interventions~* Known adverse side effect to sucroferric oxydroxide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Open-label, one arm study. Patients receive sucroferric oxyhydroxide three times daily and dose is titrated to keep serum phosphate at goal.

Based on this trial design, predict the completion outcome and termination type (if applicable).